Home Newsfeeds BTIG Downgrades Paramount Group to Neutral

BTIG Downgrades Paramount Group to Neutral

BTIG analyst Thomas Catherwood downgrades Paramount Group (NYSE:PGRE) from Buy to Neutral.

byBenzinga Newsdesk

October 19, 2022

1 minute read

BTIG analyst Thomas Catherwood downgrades Paramount Group (NYSE:PGRE) from Buy to Neutral.

Coinbase to Benefit from SEC’s Bitcoin ETF Approvals – Analyst Expects Favorable Q4

By Anusuya Lahiri

January 11, 4:32 PM

Wedbush analyst Moshe Katri maintained Coinbase Global Inc (NASDAQ: COIN) with an Outperform and raised the

COIN

Himax Tech CEO Calls Q1 Low Point, Foresees Sales Surge in Automotive Sector

By Anusuya Lahiri

May 9, 11:20 AM

Himax Technologies, Inc reported Q1 2024 revenue decline of 15.0% Y/Y to $207.55M, beating estimates. Gross margin was 29.3%. EPS was $0.07, higher than expected. Q2 guidance: 8.0-13.0% revenue growth, gross margin 31.5-33.5%, EPS $0.13-$0.17. Dividend of $0.29 declared. Stock up 6.51% premarket.

HIMX

Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes

By Lisa Levin

August 12, 9:14 AM

Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading.

Jasper Therapeutics Announces Oral Presentation Of Final Results From Phase 1 Study Of Briquilimab In Patients With AML Or MDS Undergoing Hematopoietic Cell Transplant At ASH 2023

By Benzinga Newsdesk

November 2, 9:16 AM

Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic

JSPR

BTIG Downgrades Paramount Group to Neutral

Related Posts

Coinbase to Benefit from SEC’s Bitcoin ETF Approvals – Analyst Expects Favorable Q4

Himax Tech CEO Calls Q1 Low Point, Foresees Sales Surge in Automotive Sector

Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes

Jasper Therapeutics Announces Oral Presentation Of Final Results From Phase 1 Study Of Briquilimab In Patients With AML Or MDS Undergoing Hematopoietic Cell Transplant At ASH 2023